UMIN-CTR Clinical Trial

Public title

Effects of consumption of the test food on the discomfort of the knee joint in healthy subjects

Acronym

Effects of consumption of the test food on the discomfort of the knee joint in healthy subjects

Scientific Title

Effects of consumption of the test food on the discomfort of the knee joint in healthy subjects: a randomized, double-blind placebo-controlled trial

Scientific Title:Acronym

Effects of consumption of the test food on the discomfort of the knee joint in healthy subjects

Region

Japan

Condition

Healthy Japanese subjects

Classification by specialty

Not applicable

Adult

Classification by malignancy

Others

Genomic information

NO

Narrative objectives1

To evaluate the discomfort of the knee joint after continuous consumption of the test food for 12 weeks in healthy subjects

Basic objectives2

Safety,Efficacy

Basic objectives -Others

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable

Primary outcomes

The measured values of the total score of Japanese Knee Osteoarthritis Measure (JKOM) at 12 weeks after consumption (12w)

Key secondary outcomes

1. The measured values of the total score of JKOM at 4 and 8 weeks after consumption (4, 8w)

2. The amounts of changes of the total score of JKOM between screening (before consumption; Scr) and 4w, 8w, or 12w

3. The measured values at 4w, 8w and 12w and amounts of changes between Scr and 4w, 8w, or 12w of the following items:

3-1. JKOM
visual analogue scale (VAS), the scores of pain and stiffness in knees, conditions in daily life, general activities, and health conditions

3-2. Japanese Orthopaedic Association (JOA) score
JOA score [average of both foot (right and left), left foot, and right foot], pain on walking [average of both foot (right and left), left foot, and right foot], pain on ascending or descending stairs [average of both foot (right and left), left foot, and right foot], range of motion [average of both foot (right and left), left foot, and right foot], joint effusion [average of both foot (right and left), left foot, and right foot]

3-3. Interleukin 1 beta (IL-1beta)

3-4. Interleukin 6 (IL-6)

3-5. High sensitivity C-reactive protein (CRP)

3-6. Procollagen II C-Terminal Propeptide (PIICP)

3-7. Collagen Type II Cleavage (C2C)*

4. The values of the individual items of the JKOM questionnaire and the JOA score at 4w, 8w and 12w

*Due to the outbreak of COVID-19 infection, the measurement of the originally planned marker is no longer feasible and thereby the measuring marker has been changed.

Study type

Interventional

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Duration: 12 weeks
Test food: Food containing methyl sulfonyl methane
Administration: Take ten tablets per day with water, five tablets each at breakfast and dinner

* If you forget to take the test food, take it as soon as you remember within the day.

Interventions/Control_2

Duration: 12 weeks
Test food: Placebo
Administration: Take ten tablets per day with water, five tablets each at breakfast and dinner

* If you forget to take the test food, take it as soon as you remember within the day.

Interventions/Control_3

Interventions/Control_4

Interventions/Control_5

Interventions/Control_6

Interventions/Control_7

Interventions/Control_8

Interventions/Control_9

Interventions/Control_10

Age-lower limit

20

years-old

<=

Age-upper limit

Not applicable

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Subjects aged 20 or more

4. Healthy subjects

5. Subjects who are experiencing discomfort in the knee joint

6. Subjects who are judged as eligible to participate in the study by the physician

7. Subjects who are judged in the Kellgren-Lawrence grade (KL grade) either 0 or 1 in X-ray at screening (before consumption; Scr)

8. Subjects whose JKOM score are relatively high at Scr

Key exclusion criteria

1. Subjects who have at least one previous medical history of malignant tumor, heart failure or myocardial infarction

2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)

3. Subjects who are undergoing medical treatment of knee disease such as knee osteoarthritis

4. Subjects who are currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases

5. Subjects who take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily use

6. Subjects who currently taking or using medicines (include herbal medicines, cold patch and topical medication) and supplements

7. Subjects who are allergic to medicines and/or the test food related products

8. Subjects who are pregnant, breast-feeding, or planning to become pregnant

9. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial

10. Subjects who are judged as ineligible to participate in the study by the physician

Target sample size

80

Name of lead principal investigator

1st name	Tsuyoshi
Middle name
Last name	Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com

Name of contact person

1st name	Naoko
Middle name
Last name	Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.

TEL

03-3818-0610

Homepage URL

Email

nao@orthomedico.jp

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name

Organization

CIC FRONTIER Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Co-sponsor

Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic

Name of secondary funder(s)

Organization

the ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.

Tel

03-5793-3623

Email

IRB@takara-clinic.com

Secondary IDs

NO

Study ID_1

Org. issuing International ID_1

Study ID_2

Org. issuing International ID_2

IND to MHLW

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)

Date of disclosure of the study information

2021

Year

05

Month

19

Day

URL releasing protocol

Publication of results

Unpublished

URL related to results and publications

Number of participants that the trial has enrolled

88

Results

Results date posted

Results Delayed

Results Delay Reason

Date of the first journal publication of results

Baseline Characteristics

Participant flow

Adverse events

Outcome measures

Plan to share IPD

IPD sharing Plan description

Recruitment status

Completed

Date of protocol fixation

2021

Year

05

Month

12

Day

Date of IRB

2021

Year

05

Month

12

Day

Anticipated trial start date

2021

Year

05

Month

19

Day

Last follow-up date

2021

Year

12

Month

25

Day

Date of closure to data entry

Date trial data considered complete

Date analysis concluded

Other related information

Registered date

2021

Year

05

Month

19

Day

Last modified on

2024

Year

04

Month

03

Day

Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050551